Clinical Trials for Brain Tumor

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Eligible patients have metastatic breast cancer with at least two untreated brain metastases (≥5 mm), are ECOG 0-1, and may continue concurrent hormonal or anti-HER2 treatment; participants receive stereotactic radiosurgery (SRS) to one lesion followed by pembrolizumab, an anti-PD-1 monoclonal antibody immunotherapy, to assess responses in non-irradiated brain lesions and systemically. Prior SRS is permitted if new lesions are targeted, and key exclusions include active autoimmune disease and recent complete CNS resection.

ClinicalTrials.gov ID: NCT03449238

Phase I/II Study of Stereotactic Radiation and Abemaciclib in the Management of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with hormone receptor positive, HER2-negative metastatic breast cancer and up to 15 brain metastases (measurable by RANO-BM and eligible for SRS) to receive abemaciclib (a CDK4/6 inhibitor), endocrine therapy, and stereotactic radiosurgery. Patients must not have prior whole brain radiotherapy, leptomeningeal disease, or recent abemaciclib exposure.

ClinicalTrials.gov ID: NCT04923542

A Phase IIa Study of Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab in Patients With Asymptomatic Brain Metastasis From Triple Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC) or Hormone Receptor Positive (HR+) Breast Cancer.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This study enrolls female patients with triple negative, HER2+, or hormone receptor positive breast cancer and asymptomatic, measurable brain metastases, treating them with a personalized anti-HER2/HER3 dendritic cell vaccine (designed to enhance immune targeting of HER2/HER3-expressing cells) combined with the PD-1 inhibitor pembrolizumab. Eligible patients must have ECOG 0-1 and no immediate need for local brain therapy, leptomeningeal disease, or active autoimmune/infectious conditions.

ClinicalTrials.gov ID: NCT04348747

A Single Arm Phase II Study Assessing Efficacy of Stereotactic Radiosurgery (SRS) for Brain Metastasis (BM) From Small Cell Lung Cancer (SCLC)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with histologically confirmed SCLC and up to 10 brain metastases (KPS 60–100/ECOG 0–2), without prior brain RT or leptomeningeal disease, receive stereotactic radiosurgery to all lesions. Designed to evaluate intracranial control and short-term survival (6-month OS) with focal SRS instead of whole-brain radiotherapy.

ClinicalTrials.gov ID: NCT05419076

A Single Arm Open Label Study to Determine the Safety and Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Recurrence of Glioma in Patients Who Received a Prior Treatment With 186RNL

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with histologically confirmed recurrent malignant glioma (WHO grade III–IV) who previously received 186RNL, eligible for stereotactic biopsy, are retreated with a single intratumoral infusion of rhenium-186 nanoliposomes via convection-enhanced delivery. 186RNL is a beta-emitting radionuclide encapsulated in nanoliposomes to deliver localized radiation to tumor tissue, with safety, dosimetry, and efficacy (ORR/PFS) assessed; key exclusions include multifocal/leptomeningeal disease and most infratentorial tumors.

ClinicalTrials.gov ID: NCT05460507

Preservation of Cognition and Neuropsychiatric Functioning With Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases: A Pilot Study

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with solid-tumor brain metastases scheduled for WBRT (MMSE ≥24, KPS ≥70) receive intensity-modulated whole-brain radiotherapy delivering 30 Gy in 10 fractions while selectively sparing the genu of the corpus callosum. Intended for patients without genu involvement (prior SRS allowed, no prior WBRT), this approach aims to preserve cognition and neuropsychiatric function compared with standard WBRT.

ClinicalTrials.gov ID: NCT03223922

Phase I Study of Stereotactic Radiosurgery Dose Escalation for Brain Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with 1–5 previously unirradiated, non–brainstem brain metastases (KPS ≥60) receive stereotactic radiosurgery with dose escalation to one or more eligible lesions, while other lesions (if present) receive standard SRS dosing. Excludes radiosensitive primaries (e.g., small cell, germ cell, lymphoma/leukemia, myeloma) and leptomeningeal disease; evaluates safety/MTD based on grade ≥3 toxicities over 12 weeks.

ClinicalTrials.gov ID: NCT02390518

A Phase III Trial of Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with 5–15 brain metastases (non-hematologic primaries; largest lesion <2.5 cm; ECOG 0–2) are randomized to stereotactic radiosurgery to all lesions versus hippocampal-avoidant whole-brain radiotherapy plus memantine (an NMDA receptor antagonist to mitigate cognitive decline). Excludes prior cranial RT, leptomeningeal disease, lesions near the optic apparatus, certain histologies (germ cell, small cell, lymphoma), and >15 lesions on volumetric MRI.

ClinicalTrials.gov ID: NCT03550391

Feasibility of Evaluating Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults aged 18–39 with recurrent high-grade glioma, including diffuse midline glioma, receive short-course preoperative abemaciclib (oral CDK4/6 inhibitor) followed by surgery with intratumoral microdialysis to measure CNS penetration; those meeting PK/PD thresholds may continue abemaciclib 150 mg BID with temozolomide in 28-day cycles. Excludes prior CDK4/6 inhibitor exposure and patients unable to safely undergo biopsy or on strong/moderate CYP3A modulators.

ClinicalTrials.gov ID: NCT05413304

A Feasibility Study Examining the Use of Non-Invasive Focused Ultrasound (FUS) With Oral Etoposide Administration in Children With Progressive Diffuse Midline Glioma (DMG)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Children and young adults (4–21) with progressive diffuse midline glioma of the pons and/or thalamus (including H3K27M-mutant) receive non-invasive focused ultrasound with microbubbles and neuronavigation to transiently open the BBB at tumor-adjacent sites, combined with concurrent oral etoposide (topoisomerase II inhibitor). Key exclusions include prior etoposide, implanted devices, uncontrolled seizures, significant cardiac/QTc issues, coagulopathy/anticoagulation, and inability to tolerate MRI/anesthesia.

ClinicalTrials.gov ID: NCT05762419